Isradipine
DYNACIRC
Pronunciation: iz-RA-di-peen
“Is radish dipping Dino circuit?”
What it isVascular L-type calcium-channel blocker; hypertension.
Why this oneParkinson trials were negative, and as an antihypertensive it offers no advantage over longer-acting dihydropyridines.
What limits itPeripheral edema and reflex tachycardia limit use; CYP3A4 interactions can alter exposure.
FDA-approved for
- hypertension (1990)
FDA label
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Hypertension | Adult | 2.5 mg BID | up to 10 mg/day | 20 mg/day |
Titration Adjust in 5 mg/day increments at 2- to 4-week intervals.
Renal Mild impairment: usual 2.5 mg BID starting dose (AUC increased).
Hepatic Hepatic impairment: usual 2.5 mg BID starting dose (AUC increased).
Little added benefit above 10 mg/day; adverse effects increase above 10 mg/day.
Instructions
- May be given alone or with a thiazide diuretic
Available strengths
- cap 2.5, 5 mg
Cautions
- Vasodilatory effects: dizziness, edema, palpitations, flushing, tachycardia
- Rare hypotension, heart failure, MI reported
Adverse reactions
- Headache
- Dizziness
- Edema
- Palpitations
- Flushing
- Fatigue
Pregnancy Category C; use only if potential benefit outweighs risk.
Lactation Undefined
Cost
Generic entry2006
NO BOXED WARNINGS
Principal riskPeripheral edema and reflex tachycardia
Classes and tags
Clinical profile
Legacy pregnancy categoryC
Defining liabilityHypotension and edema therapeutically; overdose can cause prolonged vasodilatory or cardiogenic shock.
Open Isradipine in the interactive console ↗
Memory aids: interaction avatars
